

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023



COELIAC UK

(A Company Limited by Guarantee)

Registered Charity Number: 1048167

Registered Company Number: 03068044

Scottish Charity Number: SC039804

Amended

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Contents	Page
Legal and administrative information	3-4
Structure, Governance and Management	5-8
Report of the Board of Trustees	9-19
Independent Auditors' report	20-23
Consolidated statement of financial activities	24
Consolidated balance sheet	25
Consolidated statement of cash flows	26
Notes to the financial statements	27 - 44

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Legal and administrative information

The organisation is a charitable company limited by guarantee, incorporated on 14 June 1995 and registered as a UK Charity on 20 July 1995. Coeliac UK is the successor organisation to The Coeliac Society which was established in 1968.

The Charity is governed by its Articles of Association which set out its objects and powers.

The Articles provide for the Board to consist of up to nine elected Trustees, two co-opted Trustees and one Trustee nominated by the Health Advisory Council. A trustee shall hold office for a period of 3 years and shall then be subject to re-election and may be re-elected for a further term of 3 years after which they must retire as a Trustee but may be re-elected as a Trustee after an intervening period of at least 1 year.

Board of Trustees

Lawrence Broadie
Maureen Burnside – Chair (until 22/02/2024)
Anne Davis (Appointed 3/08/2023)
Kate Denham (Appointed 29/08/2023)
Chris Dilloway – Chair (from 22/02/2024)
Aishah Farooq
Clive Hart (Appointed 18/04/2023)
Angeli Hemnani (Resigned 29/08/2023)
Kenneth O’Dea (Resigned 17/06/2023)
Dr Anita Patel
Professor Alan Perkins
Dr Gerry Robins
Reshma Shah (Resigned 17/06/2023)
Miranda Sheffield (Appointed 31/08/2023)
Nicola Valmas
Ife Kantonna (Resigned 6/10/2023)
Ashley Bailey (Appointed 22/02/2024)

Company Secretary

Chief Executive

Hilary Croft

Company number

03068044

Charity number

1048167

Scottish Charity number

SC039804

Registered office and operation address

Artisan
Hillbottom Road
High Wycombe
Buckinghamshire
HP12 4HJ

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Auditors

Moore Kingston Smith LLP
9 Appold Street
London
EC2A 2AP

Bankers

HSBC Bank plc
Oxford Circus Branch
196 Oxford Street
London
W1D 1NT

Lloyds Bank
21-31 White Hart Street
High Wycombe
Buckinghamshire
HP11 2HL

Investment manager

Cazenove Capital
1 London Wall Place
London
EC2Y 5AU

Solicitors

Blaser Mills
Park House
40 Oxford Road
High Wycombe
Buckinghamshire
HP11 2EE

The Charity

Structure, Governance and Management

Coeliac UK is a charitable company limited by guarantee, incorporated on 14 June 1995, and registered as a Charity on 20 July 1995 with the Charity Commission. It was also registered with the Office of the Scottish Charity Regulator in 2008.

The Charity's objectives are set out in its Articles of Association adopted on 3rd July 2021:

- improving the wellbeing and outcomes of people affected by the Coeliac condition;
- increasing awareness and knowledge and improving the care and choice for those affected by the Coeliac condition; and
- promoting research into the nature, causes, alleviation, treatment and cure of the Coeliac condition.

Public Benefit

The Trustees, in exercising their powers and duties, have complied with their duty in Section 17 of the Charity Act 2011 to have due regard to the public benefit guidance published by the Charity Commission. In preparing the report and accounts, the Trustees complied with the requirements in that guidance to report on the significant activities and achievements of the Charity in 2023. They have reported in a way that both sets out the aims and strategies of the Charity and demonstrates how the aims and activities of the Charity were carried out for the public benefit.

Management and staff

The Board of Trustees delegates the day-to-day management of the Charity to the Chief Executive who led a team of approximately 52 full time equivalent staff in 2023. Their work is supplemented at times of peak workload by a limited number of temporary staff. The staff work within the Delegation of Authority agreed by the Board. The staff agree a work plan with the Board at the beginning of the year and report progress at Board meetings throughout the year, through quarterly reporting.

The Board of Trustees appoints an HR Committee to oversee the setting of pay and remuneration for senior management and the entire organisation. Their remit is to regularly review and agree performance review arrangements; agree remuneration policies including terms, conditions and benefits; consider recommendations for individual pay on the basis of individual appraisals and to consider the Charity's human resource strategy. The committee comprises the Chair of the Board of Trustees and at least two other Trustees.

The organisation is comprised of Coeliac UK, a registered Charity, and its subsidiary The Coeliac Trading Company Ltd. The principal activity of the trading subsidiary is to raise funds on a commercial basis for the Charity to support its charitable activities. The subsidiary is governed by two directors appointed from the senior management team of the Charity, one Trustee from the Board of the Charity, and chaired by an independent director.

In December 2023, the assets and operations of The Coeliac Trading Company Ltd were transferred to Coeliac UK. Following the transfer, The Coeliac Trading Company Ltd became dormant and ceased to trade.

The Board of Trustees

The Board of Trustees lead the Charity in setting its strategic direction and agreeing objectives and plans to deliver the Charity's aims. The Board monitors and evaluates the progress of the Charity to ensure it achieves those objectives and plans.

The expertise within the Board is substantial, wide-ranging and importantly complementary. Trustees include director-level individuals from finance, fundraising, HR, marketing, law and healthcare backgrounds. All Trustees are volunteers committing many hours to the work of the Charity.

The Board's Committees/Councils

The Board delegates some of its responsibilities to specialist groups to provide particular focus and expertise on key issues and opportunities:

Audit Committee

Ensures the robustness of the Board's overall financial and risk monitoring. The role of the Committee is to support the Board of Trustees in monitoring the adequacy of the Coeliac UK's corporate governance and control systems by offering objective advice on issues concerning the risk, control and governance of the organisation and associated assurances provided by external audit and other processes. It ensures the Charity's financial management meets the standards of good practice accepted by the Charity Commission and Companies House.

People Committee (see Management and staff above)

Oversees the Charity's HR policies ensuring they are legally compliant and fit for purpose.

Executive Action Committee

Allows the Board to retain control in crisis situations when the full Board may not be able to be convened. The Committee would only be called upon in emergencies and was not invoked in 2022.

Health Advisory Council (HAC)

Brings expert insight into health issues related to coeliac disease, associated research and advice on related policies and activities. The Council draws upon a wide range of expertise to reflect all aspects of healthcare and includes representation from across all four UK nations.

Food Standards Committee (FSC)

Provides the Charity with additional technical expertise and independent appraisal of the standards applied to its licensing and accreditation activities. It also engages with other industry and regulatory bodies to ensure the exchange of ideas and state of the art information.

Research Strategy Board (RSB)

In addition to bringing expert knowledge and experience, the RSB fulfils governance requirements for the review and development of the Charity's research strategy which underpins the Charity's Research Fund.

Research Awards Panel (RAP)

Manages the awards process for grants under the Research Fund. It provides the Charity with expert insight and fulfils governance requirements for the review, funding and management of the Charity's research awards in line with the Charity's Research Strategy. The Panel reports to the Board of Trustees.

Fundraising Committee

Brings the Charity expert insight and fulfils the governance requirements for the detailed scrutiny and oversight of the fundraising undertaken for the Charity including for the Research Fund.

Commercial Committee

Provides the Charity expert insight to help plan the Commercial Services strategy and deliver its activities.

Board of the Trading Company

During the year, the assets and operations of The Coeliac Trading Company Ltd were transferred to Coeliac UK, and the Directors of the subsidiary have decided that the company shall remain dormant for the foreseeable future.

Meeting protocol

The Boards and committees continued to use a combination of face-to-face meetings, video calls and teleconferences during the year to review plans and activities of the Charity and ensure the cost effectiveness of their operations.

Recruiting and supporting Trustees

The Board of Trustees regularly undertakes an audit to identify current and future skills gaps. Roles are advertised widely both in the Charity's communications to members and on recruitment websites open to all. The selection process comprises shortlisting based on CVs and supporting statements, followed by an interview panel for shortlisted candidates. Following appointment, new Trustees are provided with induction packs, formal training as required for the role, and sessions spent with key staff.

Our approach to Fundraising

As a charity registered with the Fundraising Regulator, we strive to achieve the highest standards in all our fundraising activities, referring to all relevant professional and statutory bodies as guidance and regulation develops. Our aim to develop positive long-term relationships with our members, donors and supporters underpins all our actions in this area.

Coeliac UK operates with a small team of in-house staff to lead and develop its fundraising. Fundraising staff are expected to act professionally at all times, follow the Fundraising Regulator's Code of Conduct and are encouraged to undertake training to develop their knowledge. Fundraising staff receive a salary but are not eligible for a performance bonus.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

We also use the services of several carefully selected external companies who provide specialist skills to help us deliver specific activities. These include a telephone agency, as well as a raffle and lottery manager. With each of these companies, we have signed agreements, committing them to adhere to both the letter and spirit of the regulations.

Any complaints that fundraising activity may generate are recorded and investigated by the appropriate line manager to ensure future learning opportunities in fundraising. Coeliac UK is pleased that its fundraising activity generates few complaints annually. In 2023, we received 4 complaints, 3 of which related to our external partners, and one of which related to frequency of contact from the Charity. All complaints were quickly resolved without escalation.

Managing risk

The Trustees are responsible for ensuring appropriate financial and other controls are in place. At Coeliac UK, the role of risk management is delegated to the Audit Committee who review the risk quarterly and report back to the full Board.

A risk register is used by the Board and staff to review the main risks and uncertainties, and systems put in place for management and mitigation. The register is regularly updated and monitored by the executive team and Board as work progresses through the year.

The key risks are made up of financial, operational, regulatory, external and strategic risks; and the main residual high risk identified (after mitigating actions) in 2023 was that income raised from all fundraising channels does not meet the budget target for net income.

Report of the Board of Trustees

The Board of Trustees who are the Charity Trustees, and Directors of Coeliac UK ('the charitable company'/'the Charity'), have pleasure in presenting their report, which incorporates the report of the Directors for the purposes of company law, and the accounts for the year ended 31 December 2023.

Amended financial statements

These financial statements have been amended from those previously approved by the Trustees on 16 April 2024. Expenditure has been reclassified to correctly represent the activity in the year. These amended financial statements:

- Replace the original accounts,
- Are now the statutory accounts, and
- Are prepared as there at the date of the original accounts.

Introduction

2023 saw Coeliac UK return to growth in many areas. Our membership has returned to post-pandemic levels and is on an upward trajectory; more people know about us; satisfaction with our services is higher than ever; we have re-engaged with researchers to advance our "journey to a cure"; and our overall audience is growing and becoming more engaged. Our financial position remains strong, and we finished the year ahead of where we expected.

This is a very good position for us to be in as we enter 2024.

All this has happened despite some significant operational challenges, including a relatively high level of staff turnover and consequently many gaps in resource, ongoing systems migrations, and the upheaval of our move to a new office, although much better suited to our needs.

We are grateful to all our staff, volunteers, supporters, partners, and donors, who help us to do our important work every day. With the NHS in crisis, Coeliac UK really is the place where people with coeliac disease and those needing to live without gluten can turn to for help. We know people value our work, and we continue to be ambitious to reach more people and deliver even better support and outcomes for our community. We provide vital services and information to support those diagnosed or caring for someone with coeliac disease in living a gluten free life and guidance and advice to those seeking diagnosis. We also lead the campaigning alongside the health and food sectors to educate and raise awareness to increase understanding of the condition and the treatment required. With growing support, in the longer term, we will continue to fund research to improve management of the condition, the development of treatments and ultimately a cure.

From initial diagnosis Coeliac UK provided the explanation as to what's happening and lots of supportive information on how to manage the gluten free diet and eating out ... the information was there to inform choices. I hope Coeliac UK can continue to grow and support other sufferers.
Keith, York

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Our major achievements for 2023 included:

- Returning to membership growth – retaining 96% of our existing members and gaining 15% more new members than in 2022.
- Launching new opportunities for our community to connect with one another – launching our Coeliac UK Teen Virtual Club for 12-15 year olds, our new Local Meet Ups around the UK and hosted a very popular Gluten Free Food Market.
- Continuing to develop strong commercial partnerships with the gluten free food industry and grow our income vs 2022 – onboarding 17 new partners in our food safety/licensing schemes.
- Running a successful “Journey to a Cure” research fundraising appeal – raising over £110k.
- Receiving strong applications to award new grants for ground-breaking research into coeliac disease (starting in 2024).
- Increasing our campaign reach to 5.2m impressions and doubled the number of self-assessments completed to over 11k, as part of our Coeliac Awareness Week campaign.
- Benefitting from nearly £1 million through Gifts in Wills, reflecting both the lifetime of support legacy donors have received, and our focus on this area of fundraising.

Key Activities for 2023

Objectives and activities delivered in 2023 continued to align with the 2020-2025 strategic themes. Some highlights include:

Reach

- In our 2020-2025 Strategic Objectives, we set targets of awareness of Coeliac UK at 50%. Since 2019 we have increased our awareness from 30% to 42% (YouGov, 2023).
- Coeliac Awareness Week ran from 15-21 May and focused on the lesser-known symptoms of coeliac disease (mouth ulcers, anaemia, fatigue, neurological symptoms, unexplained infertility, and recurrent miscarriage), that can often confuse, and subsequently contribute to the average diagnosis period for adults of 13 years from onset of symptoms. Our target is to reach the 500k people who are currently undiagnosed. The campaign reached 5.2 million impressions, £3.2m PR value, Facebook live broadcast views 24.4k and the number of people who completed the self-assessment was double last year’s figure at over 11k. There was also community involvement with templates and ideas provided for user generated content where bloggers, members, other followers could spread the word and share their own stories, plus fundraising activity.
- Our Cost-of-living gluten free report launched in March 2023 and ran across multiple media channels (and is still continuing); raising awareness of the financial challenges of adhering to a strict medically prescribed gluten free diet, the only current treatment for coeliac disease. Asking policy makers and the food industry to make gluten free food more affordable and accessible for the coeliac community. It was picked up by 39 media outlets at the time with 26m opportunities to see (OTS) and PR value of £2.1m, including a long video piece with a case study on 11 of the ITV news regions.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

- We launched our Podcast '100 things I wished I'd known about being gluten free'. The pilot episode launched in December and aligned with our campaign "A Christmas Wish" where our community was asked what wishes they had for the coming year and what they'd like to see change. (It also incorporated a cash appeal.) Hosted by Hilary Croft, Becky Excell and Aimee Vivian they talked about their experience of Christmases past, and their wishes for the future. Resulting in 114k views and 2333 downloads. The same question about future change was asked of our community on a Facebook Live with Becky Excell – 21k reach, with 14.2% engagement rate.
- ITV's This Morning segment in December 2023, where Vanessa Feltz made dismissive comments about needing to live gluten free, led to us writing an open letter to ITV – resulting in 1m impressions on our social channels; a follow up GP segment the following day; a cooking slot for Becky Excell within a week; and a slot for our case study and a health care professional in early January 2024. We are also in talks with them to provide additional coverage.
- New member acquisition increased by 15%, with even more new members opting for our lower cost, digital membership package, and we welcomed back over 1,400 lapsed members.
- Continued investment in our digital channels: including development of the new Live Well Gluten Free app that launched in January 2023 with enhanced features being rolled out across the year.

***Coeliac UK helped me to manage my condition, and it's reassuring to know I am not alone, have a point of reference and can seek answers, recipes, and direction when necessary.
Roger, Bexhill on Sea***

Research

- We managed the process for grant applications for two different funding streams: a basic science research call of £250k, and our revised sponsored dissertation scheme for postgraduates with 2 x £5k grants available. Around 150 members participated in the Member Review Panel to help us select what research to fund with the awards being finally granted in early 2024.
 - Delivered successful fundraising activities to support our research work, raising over £126k.
 - Launched three new research projects, awarded from the 2022 research call.
 - Completed the fourth of our Innovate UK research projects. This project explored the use of artificial intelligence to assess biopsy samples in the diagnosis of coeliac disease. This project provided preliminary data that has been used to secure follow-on funding of £620k from the National Institute of Health and Care Research (NIHR) to allow continuation of research in this area. This means the return on investment is about £3.60 for every £1 originally awarded by Coeliac UK and Innovate UK. Coeliac UK are leading on the patient and public involvement and engagement within the NIHR funded project.
 - Delivered another series of research talks for healthcare professionals, providing them with continuing professional development and information to best support patients with coeliac disease.
-

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

- Completed our Eating Out survey: designed to provide a greater understanding of the gluten free consumer and their experiences of eating away from the home. Around 4,500 people completed the survey with results due to be published in the first quarter of 2024.
- Published our cost-of-living report, March 2023 and further expanded our knowledge of gluten free consumers' experiences of access and availability of gluten free food both in store and online with over 1000 people engaging in an online survey. A second report is due for publication in the first quarter of 2024.

Experience

- We returned to hosting our very own Gluten Free Food Market with the invaluable support of our volunteers in Cardiff. Over 700 attendees enjoyed the delights of local and national gluten free food producers, and it was a fantastic opportunity to connect with existing and new members of our gluten free community.
- We continued to evolve our social and digital offering with more video content, more personal story telling and more targeted digital campaigns to drive awareness and increase engagement. This is currently stable at 4% despite changes across Meta and X. Followers increased by 16% through the year, now standing just below 200k.
- In June we piloted a new opportunity to help teens connect with one another and share experiences through an online meet up. Our teen volunteers helped us to develop resources to share on eating out and travelling gluten free which was well received. Following its success, we coordinated two further events for our Teen Virtual Club along with our volunteers and covered the subject of explaining Coeliac disease and the gluten free diet to friends and family.
- Our network of community volunteers continued to provide connection and support through a range of coordinated events throughout the UK as well as peer support via our Member2Member programme. We're also thrilled at successfully launching 20 new regular Local Meet Up events within local communities.

Our work in Devolved Nations

Coeliac UK is a national organisation with an international reach. In the UK, we are committed to supporting needs of our community wherever they reside and recognise there are differences in each of the UK's nations in terms of government, health policy and practice, and community priorities. In 2023, we continued to build on our work supporting people with Coeliac disease in the UK's devolved nations as follows:

- Carrying out an All Party Parliamentary Group (APPG) inquiry into diagnosis with key stakeholders and publishing a report at a Parliamentary round table.
 - Hosting a Scottish Parliamentary reception with the Minister for Public Health and MSPs from across the political spectrum. Meeting with the Scottish Dietetic Network alongside Peter Gillett, Consultant Paediatric Gastroenterologist, and with members of the Edinburgh and Glasgow local groups.
 - Hosting two meetings with the long-established Cross Party Group in Wales under the chairmanship of Plaid Cymru Leader, Rhun ap Iorwerth MS/AS.
 - Meeting with the Northern Ireland dietetic network and local group committee, and supporting Western Trust Awareness Week event and media coverage.
-

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

- Tabling Parliamentary questions and Early Day Motion/Motion to Parliament/Statement of Opinion in each national parliament (except NI Assembly that was not sitting) as part of Awareness Week activity.

It's important to me that there is an organisation dedicated to helping those with coeliac disease and raising awareness about this condition. It's important that I don't feel alone struggling with Coeliac disease and I have support from other people.

Alyson, Sandhurst

Partnerships

- Continued collaboration with the food industry to improve access and availability of gluten free food consumers can trust.
- For our Gluten Free Accreditation (GFA) scheme for eating out/catering, in 2023 we renewed 34 existing partners, and extended our partnerships by 5 new members including Bills restaurant chain in England and Wales. This brings our coverage of outlets under our scheme to over 3,000.
- For our Crossed Grain Trademark (CGT) packaged brand food safety scheme, we had 158 partners renew in 2023 and had 12 new partners onboarded to the scheme. We now have over 2,000 products bearing our trademark, which provides gluten free consumers with the confidence they need.
- Continued development of significant food industry partnerships, including securing significant advertising and sponsorship support from Co-op, Panasonic, White Rabbit and Nestle GoFree.
- Continued strategic partnership with ThermoFisher to support diagnosis and awareness campaigns.

Working with Coeliac UK has given us the opportunity to critically look at our allergy process as a whole and GF menu options. Whilst Bill's has had an "Avoiding Gluten" Menu for many years it is great that we can now offer our guests a "Gluten Free" menu with confidence that our systems and processes are in line with Coeliac UK standards, giving our guests more choice and confidence. In addition to this the accreditation has allowed us to join the Coeliac UK network, bringing Bill's to Coeliacs across the UK.

Eunan – Health and Safety Manager for Bills

Global Leadership

- Worked with AO ECS (Association of European Coeliac Societies) to improve support for its members and extend and improve the European Licensing Scheme (the Crossed Grain trademark licensing scheme, designed to improve the accessibility and safety of gluten free food across Europe). Represented AO ECS as an observer at the Codex Committee on Food Labelling (CCFL) meeting in Quebec.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

- Continued to provide an Executive Officer for the ISSCD (International Society for the Study of Celiac Disease), assisting with a change in the organisation's constitution, managing the ISSCD website, launching a mentee in mentorship programme, creating content for members' newsletters, and assisting in the organisation of the International Celiac Disease Symposium, Sheffield 2024.
- Attended the Prolamin Working Group (PWG) annual meeting in the Netherlands. The PWG is an international group of physicians, chemists, food scientists, and nutritionists working together to perform and coordinate research on the analysis of gluten in food and on the evaluation of clinical and nutritional aspects of Coeliac disease.

Information from Coeliac UK has helped me understand my symptoms. I suffered from unexplained anaemia, headaches, and bone pain. I was unaware these were symptoms of coeliac disease. Fortunately, my GP was aware which led to diagnosis. The food label scanner is extremely useful, and I use it all the time.
Carolyn, Dalbeattie

Plans for 2024

2024 sees the last year of our current five-year strategy. This year we plan to review and update our strategy starting with renewing and strengthening our overall proposition. This will ensure that we continue to focus on the things that will deliver the outcomes most valued by our beneficiaries. We will consult with those that we currently impact, as well as those not currently engaged with us, to help us think widely about where we focus, in addition to the existing insight we have gathered on what people value in our work. We are excited to see where this takes us and see this as an opportunity to reflect on what we deliver for our community in a post-covid/cost of living crisis world. We still see significant opportunities for extending our reach and service offering, bringing real benefits to the community, and want to re-ignite our commitment to delivering this through the lens of an updated strategy.

Alongside the proposition and strategy work, the Charity will continue to focus on delivering objectives that are aligned with our current strategic themes - in addition to "business as usual" activity, we have the following plans:-

Reach

- The first half of 2024 will see a range of activities supporting our key objectives of awareness, diagnosis, partnerships, and global leadership. The same focus on food safety, advocacy, awareness, and diagnosis will continue across the whole year.
- Eating out survey, March 2024: this report highlights the importance of wider provision of gluten free food for people with coeliac disease. Key statistics will be extracted to create two press releases – one for business and one for consumer audiences. The numbers will also be used to open conversations with new commercial partners and reinforce the value of the Gluten Free Accreditation Scheme (Eating Out Food Safety) with existing partners. Alongside this, we also have a Mystery Diner activity to capture the reality of our community's experiences when dining out.
- Cost of Living report #2, April 2024: The results of the second survey around the affordability and accessibility of gluten free foods for those that need it will be published in April. There will be a press release issued plus post-publication, we intend to take the views of our community to 10 Downing Street, where we'll hand in our petition for greater focus from the government on the need for provision of gluten free food.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

- Coeliac Awareness Month, May: this has been extended to cover the whole month of May to allow our members and commercial partners to have greater availability to get involved, it also works more effectively for the media. This year's theme is an evolution of the 2023 campaign 'Coeliac disease is different for everyone' with a creative refresh and 5 case studies – and whereas last year was focused on symptoms, this one is focused on the importance of diagnosis and uses storytelling to drive the message home. There will be different communications for our existing community and for the 500k people who are yet to be diagnosed and who may not even be aware that their symptoms could be coeliac disease. The call to action for this aspect will be to take our online 'is it coeliac disease' self-assessment to see if they should be tested and will be distributed widely through digital advertising and paid for social media.
- Establish engagement with the government in Northern Ireland now it has been restored and further our engagement with the government in Scotland in line with the successful model in place in Wales. This will ensure we have champions at the heart of each of the UK's four parliaments, enabling us to drive policy change for the benefit of the coeliac community.

Research

- Provide support and collaborate on four external research projects funded by the National Institute for Health and Care Research (NIHR) ensuring the coeliac community can provide meaningful input into the planning, conduct and dissemination of the research. The four projects span the areas of diagnosis, management, and psychological support.
- Maintain strict governance of our research programme and funded research, through our Research Strategy Board and Research Awards Panel.
- Conduct surveys to gain greater understanding of the level of post diagnosis care offered to the coeliac community. We will use the information to underpin our advocacy work.
- Continue to offer small grants to postgraduates in support of their dissertation focused on coeliac disease or the gluten free diet, to entice early career researchers to take an interest in the field.
- New fundraising campaigns to build up the Research Fund as part of "Journey to a Cure" to fund submitted research projects.

Experience

- Prior to the launch of the new website (and Brand Proposition) in the first quarter of 2025, we will be revising the navigation of the existing website to make the user experience simpler, and therefore simplify the process of finding information and engaging with the Charity.
- Deliver the next phases of the new Live Well Gluten Free app to include more features to help people with coeliac disease to manage their gluten-free diet – recipes, videos, blogs, personalisation etc.
- Continue to develop and deploy automation solutions to improve efficiencies internally and user journey externally, including donations, membership, commercial partner sign ups – which includes a new commercial microsite launching in the first half of 2024.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

- Continue to foster an engaged, supportive, and inclusive community by coordinating more valuable touch points through our own and volunteer led events, activities, and meetings.
- Look to develop support collateral in alternative formats to meet the needs of our diverse community.

Partnerships

- Continue to grow our Food Safety Schemes securing 48 new partners for packaged brands and 30 new partners for catering/eating out.
- Continue to work with the Association of European Coeliac Societies (AOECS) to roll out the "Gluten Free Alliance" brand to commercial customers in the UK and beyond to increase the strength and reach of our gluten free food safety schemes.
- Develop corporate fundraising partnerships with new and existing partners.

Global Leadership

- Work with ISSCD, AOECS and other national coeliac societies and organisations, to improve international research collaboration.
- Assist and participate in the International Celiac Disease Symposium, Sheffield, UK, September 2024.
- Further develop and improve the gluten free food safety schemes worldwide, in partnership with AOECS and other international and national coeliac organisations.

Financial Review

Overview

The Charity has three main sources of funding: membership fees, commercial services our restaurant accreditation scheme and licensing of the Crossed Grain Trademark), and fundraising from donations (including from gifts in wills). We also raise money through our raffles and lottery, and through grant income.

These funds enable us to provide services and information to support those diagnosed or caring for someone with coeliac disease in living a gluten free life and in providing guidance and advice to those seeking diagnosis. We are actively engaged in campaigning with the health and food sectors to educate and raise awareness to increase understanding of the condition and the treatment required. In the longer term, these income streams enable the Charity to fund research to improve management of the condition, the development of treatments and ultimately a cure.

The Charity's total income in 2023 was £4.2m, an increase of £0.1m from £4.1m income in 2022. Income from trading activities and charitable activities fell slightly from £2.5m in 2022, to £2.4m in 2023. The income from donations and legacy increased to £1.7m, £0.1m higher than gifts received in 2022; we also raised a further £0.5m from other sources, including the raffle and lottery. Following the cautious re-entry to the investment markets in 2022, investment income benefitted from a full year in the market generating £65k in 2023 up from £17k in 2022.

Expenditure in 2023 increased to £4.1m, £0.6m more than the £3.5m spend in 2022, primarily reflecting an increase in our investment in research. We have also invested in the organisation, especially our Commercial Services team as we seek to develop more relationships with licensed retailers and restaurants providing wider choice to those living with Coeliac disease.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

As a result of the above, overall, the Charity achieved a net surplus of £119k for 2023. We are pleased with this better than budgeted performance; we had planned for 2023 to be another year of consolidation as the Charity continues the slow journey of re-building after the extended impact of Covid, and investment in the organisation as we make the Charity fit for the future.

Following a small loss of £16k in 2022, our investment assets rebounded slightly in 2023, generating a small gain of £24k.

Our focus in 2024 will be on continuing to develop a portfolio of sustainable income streams, and careful management of expenditure, to ensure that we achieve a good return on investment for our members and supporters and deliver improving outcomes for our beneficiaries.

Investing in research

We are pleased to report that our total research expenditure during the year increased significantly from £135k to £275k, over 6% of income. We had planned to make a further award, but due to unforeseen circumstances this slipped in to early 2024. Added to the further awards planned, 2024 will likely see our largest ever research spends.

Investment policy and Performance

The Charity's investments are managed by Cazenove Capital, to provide a reasonable and growing income over the long term, commensurate with a moderate but not excessive degree of risk. The Charity will not invest in high risk instruments, such as derivatives, hedge funds, covered warrants or spread betting.

In August 2022, the Charity cautiously invested £340K in the Charity Responsible Multi-Asset Fund managed by Cazenove. This was following the divestment of the surplus cash held in the Cazenove multi asset fund in 2020, to safeguard the charities assets and restricted funds due to the volatility the stock market experienced during the COVID pandemic.

During 2023, we moved the remaining £623k funds from the Cazenove Cash Account to the Charity Responsible Multi-Asset Fund, ending the year with total investments of £983k.

Most of the remaining cash balance is held in our HSBC accounts, £600k of which was invested in short-term money-market accounts, and the balance in overnight higher interest accounts to get a better return.

Bank interest received from our cash deposits in 2023 was over £40k which compares favourably with the £15k achieved in 2022. We also received investment income, in the form of dividends, to the value of £24k compared with just £2k in the prior year.

The Charity regularly reviews its cash and investment position and subject to ongoing liquidity requirements will consider further investment in 2024.

Reserves policy

The Board recognises the need to hold charitable funds as free reserves to safeguard the continuity of provision of basic services, to fund periods of expenditure in excess of revenue and to fund unexpected expenditure.

As part of the 2023 year-end review process, the Board of Trustees used Charity Commission guidelines to update the reserves policy.

The Board agreed to a policy that sufficient reserves will be held to ensure the Charity can continue to operate and meet its charitable commitments, should there be a time when

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

income has been adversely impacted. This is to allow time to assess and implement the future options for the Charity. Excess reserves will be designated for a specific activity when an appropriate and timely use of the funds has been identified and agreed by the Board. In the event there are no extra reserves, the Board may utilise the operational reserves to meet any of the above needs should they arise, subject to a cost benefit analysis.

The target level of reserves as at 31st December 2023 has been calculated at £810k, being the mid-point within the range £640k to £980k. The Reserves target is calculated by assuming an average reduction in forecast income of 24% offset by a forecast reduction in discretionary costs, equal to a reduction in total costs of approximately 7.5%. We ended the year with unrestricted reserves of £1,633k, some £800k above the target. These surplus reserves will be reinvested in our charitable activities over the next strategic period, increasing our support to those living with Coeliac disease.

The Board also wish to maintain a level of liquid reserves that ensures the Charity is able to meet its obligations as they fall due. The level of liquid reserves required and liquid reserves available is reviewed regularly throughout the year. As at 31st December 2023, the Charity had £2.25m in liquid assets (cash and other liquid investments).

Of our restricted reserves of £571k, we had £492k held for our Research Fund. Sometimes, we raise funds solely for research to build a sufficient sum to launch a research call for grant applications. In 2023 we put out a new research call to the value of up to £250k. The grant award will be made for research commencing in 2024. Of our designated reserves, £12k is held for research projects, while £81k is funds for our local voluntary support groups allowing groups to actively provide support to members in their local area.

Responsibilities of the Board of Trustees

The Board of Trustees (who are also directors of Coeliac UK for the purposes of company law) is responsible for preparing the Report of Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Board of Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the charities SORP FRS102;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

The Board of Trustees is responsible for keeping adequate accounting records which are sufficient to show and explain the charitable company's transactions and which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 and the Charitable Company's constitution. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the Board of Trustees are aware:


- there is no relevant audit information of which the charitable company auditor is unaware; and
- the Board of Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Board of Trustees is responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of the financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the Special Provisions of Part 15 of the Companies Act 2006 relating to Small Companies.

This report was approved and authorised for issue by the Board of Trustees on 16th April 2024 and signed on their behalf by

Chris Dilloway



Chair

Registered Company Number: 03068044

***On diagnosis I felt I had been shut in a long dark tunnel. But with all the help and regular emails, recipes, and the magazine dropping through the door. I could see a light at the end of the tunnel, and I don't feel alone - there's someone who understands. Thank you, Coeliac UK.
Susan Norwich***

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

Opinion

We have audited the amended financial statements of Coeliac UK (the parent charitable company') and its subsidiaries (the 'group') for the year ended 31 December 2023 which comprise the group statement of financial activities, group and parent charity balance sheet and group statement of cash flows and notes to the amended financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). These amended financial statements replace the original financial statements approved by the trustees on 16 April 2024.

The amended financial statements have been prepared in accordance with The Companies (Revision of Defective Accounts and Reports) Regulations 2008 and as such do not consider events which have taken place after the date on which the original financial statements were approved.

In our opinion the amended financial statements:

- give a true and fair view of the charitable company's state of the affairs of the group and the parent charitable company as at 31 December 2023 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the amended financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the original financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Emphasis of matter - Amendment of expenditure classification

We draw attention to note 1 of the amended financial statements, which describes why amended accounts have been issued. Our opinion is not modified in this respect.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact.

We have nothing to report in this regard.

Other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Board of Trustees which includes the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Board of Trustees which includes the Directors' Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Board of Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemption in preparing the Report of the Board of Trustees and the Strategic Report.

Responsibilities of Trustees

As explained more fully in the Statement of Responsibilities of the Board of Trustees set out on page 15, the Trustees (who are also the directors of the parent charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under the Companies Act 2006 and under the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities Act 2011, the Charity SORP, the Charities and Trustee Investment (Scotland) and UK financial reporting standards as issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Independent auditors' report to the members and trustees of Coeliac UK

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members and trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Moore Kingston Smith LLP.

James Saunders (Senior Statutory Auditor)
Moore Kingston Smith LLP
Statutory Auditors

3 September 2024

9 Appold Street
London
EC2A 2AP

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Consolidated statement of financial activities (including consolidated income and expenditure account)

	Notes	Unrestricted funds	Restricted funds	2023	2022
		(£)	(£)	Total	Total
				(£)	(£)
Income					
Donations and legacies	2	1,611,891	125,728	1,737,619	1,566,102
Income from charitable activities	2	1,946,197	35,475	1,981,672	2,032,931
Income from trading activities	2	466,739	-	466,739	438,473
Investment income	2	64,999	-	64,999	16,933
Total income		4,089,826	161,203	4,251,029	4,054,439
Expenditure					
Expenditure on raising funds					
Donations and legacies		370,365	-	370,365	241,092
Trading activities		423,947	-	423,947	326,531
Expenditure on charitable activities	3	3,171,155	156,374	3,327,529	2,923,831
Other expenditure		-	-	-	24,158
Total expenditure		3,965,467	156,374	4,121,841	3,515,612
Net gains/(losses) on investments	11	24,798	(851)	23,947	(16,152)
Net income/(expenditure)for the year	7	149,157	3,978	153,135	522,675
Balances brought forward		2,036,718	566,855	2,603,573	2,080,898
Total funds carried forward		2,185,875	570,833	2,756,708	2,603,573

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The notes on pages 27 to 44 form part of these financial statements.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023


Consolidated balance sheet

	Notes	GROUP		CHARITY	
		2023 £	2022 £	2023 £	2022 £
FIXED ASSETS					
Tangible assets	10	156,996	28,568	156,996	105,264
Intangible Assets	10	115,172	105,264	115,172	28,568
Investments	11	982,580	323,848	982,582	323,850
		<u>1,254,748</u>	<u>457,680</u>	<u>1,254,750</u>	<u>457,682</u>
CURRENT ASSETS					
Investment & deposits	11	-	623,357	-	623,357
Debtors	12	1,604,690	1,008,099	1,716,594	1,211,568
Cash at Bank		1,269,542	1,692,267	1,157,636	1,431,807
		<u>2,874,232</u>	<u>3,323,723</u>	<u>2,874,230</u>	<u>3,266,732</u>
CURRENT LIABILITIES					
Creditors - falling due within one year	13	(1,372,272)	(1,137,830)	(1,372,272)	(1,080,839)
NET CURRENT ASSETS		<u>1,501,960</u>	<u>2,185,893</u>	<u>1,501,958</u>	<u>2,185,893</u>
Total assets plus current liabilities		<u>2,756,708</u>	<u>2,643,573</u>	<u>2,756,708</u>	<u>2,643,575</u>
Provisions for liabilities and charges	14	-	(40,000)	-	(40,000)
NET ASSETS		<u><u>2,756,708</u></u>	<u><u>2,603,573</u></u>	<u><u>2,756,708</u></u>	<u><u>2,603,575</u></u>
The funds of the charity					
Unrestricted funds					
Designated	15	93,223	98,291	93,223	98,291
General		2,092,651	1,938,427	2,092,651	1,938,429
		<u>2,185,875</u>	<u>2,036,718</u>	<u>2,185,875</u>	<u>2,036,720</u>
Restricted funds	16	570,833	566,855	570,833	566,855
Total charity funds		<u><u>2,756,708</u></u>	<u><u>2,603,573</u></u>	<u><u>2,756,708</u></u>	<u><u>2,603,575</u></u>

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011. These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

As permitted by s408 Companies Act 2006, the parent charity has not presented its own Statement of Financial Activity and related notes. The parent charity's profit for the year was £153,136 (2022: £522,675).

Approved by the Board of Trustees and authorised for issue on 03/09/24 these financial statements are signed on their behalf by:



Chris Dilloway - Chair

Company number: 03068044

The notes on pages 27 to 44 form part of these financial statements.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Consolidated statement of cash flows		2023	2022
	Notes	£	£
Cash flows from operating activities:			
Net cash provided by operating activities	22	(270,481)	(119)
Cash flows from investing activities:			
Dividends, interest and rents from investments		24,454	2,099
Bank interest		40,545	14,833
Purchase of tangible fixed assets		(205,816)	(133,980)
Purchase of investments		(634,783)	(340,000)
Net cash used in investing activities		<u>(775,600)</u>	<u>(457,048)</u>
Increase in cash and cash equivalents in the year		(1,046,081)	(457,167)
Cash and cash equivalents at the beginning of the year	22	2,315,623	2,772,790
Total Cash and cash equivalents at the end of the year	22	<u>1,269,542</u>	<u>2,315,623</u>

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

1 ACCOUNTING POLICIES

1.1 Basis of preparation

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK (FRS102) and Charities SORP (FRS 102) and the Companies Act 2006.

Coeliac UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

There are no material uncertainties about the charity's ability to continue as a going concern. The charity's planned activities, together with its financial position; management of risk and approaches to investments, cashflow and reserves are described in the Report of the Board of Trustees. As a consequence, the Trustees believe that the charity is well placed to manage its risks successfully despite the current uncertain economic outlook. The Trustees have a reasonable expectation that the charity and the group have adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and accounts.

1.2 Local groups and accounting policy

The local groups record their income and expenditure on a receipt basis. At the end of the financial year, each group submits a return of its income and expenditure which is included in the Statement of Financial Activities and the Balance Sheet.

1.3 Income

Income from web advertising, sponsorship and licensing, and accreditation is deferred on a proportionate basis over the life of the contract. All other income is recognised when the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Donations and legacies includes donations and gifts, legacies, and all other income that is in substance a gift made on a voluntary basis. It also includes grants of a general nature provided by government and charitable foundations which are not conditional on delivery of certain levels or volumes of a service. The donation may be made towards the general aims of Coeliac UK (unrestricted), or towards a specific service or aim (restricted). Donations are recognised on receipt of the donation, or if earlier, at the point where there is a written obligation for a donor to pay a specified donation. Legacies are recognised at the point entitlement is established, receipt is considered probable and the estate value can be estimated reliably.

1.4 Cost allocation

Shared costs have been allocated on the following basis:

Description	Method of apportionment
Depreciation	Head count
Information technology	Head count
Support staff costs	Head count
Office costs	Head count

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

1 ACCOUNTING POLICIES (Continued)

1.5 Grants

Grants payable are payments made to third parties in furtherance of the charitable objectives.

Grants which are free from specific conditions are recognised in full as soon as there is a legal or constructive obligation committing the charity.

Multiyear grants are conditional on an annual review of progress which will determine if future funding is provided. Due to this condition only one year's funding commitment is recognised.

1.6 Restricted funds

Restricted funds are to be used for specific purposes as specified by the donor. Expenditure which meets these criteria is charged to the fund.

1.7 Depreciation of fixed assets

Provision is made for depreciation on all tangible assets at rates calculated to write off the cost, less estimated residual value of each asset over its expected useful life, as follows:

Furniture and fittings	20% p.a. straight line
Computer equipment	33.33% p.a. straight line

1.8 Investments

Investments held as fixed assets are revalued at mid-market value at the balance sheet date.

1.9 Leasing

Rental payable under operating leases are charged against income on a straight-line basis over the lease term.

1.10 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of obligation can be measured reliably. Costs are analysed between expenditure on charitable activities and costs of raising funds of the charity.

Any direct costs are allocated between restricted and unrestricted funds as incurred.

1.11 Designated funds

Designated funds are unrestricted funds earmarked by the board of Trustees for particular purpose.

1.12 Pension

The charitable company operates a group personal money purchase pension scheme. The pension cost charged in the financial statements represents contributions payable by the charity during the financial year.

1.13 Basis of consolidation

The group accounts consolidate the accounts of Coeliac UK and its subsidiary undertaking on a line by line basis. The accounts are made up to 31 December 2023. No separate statement of financial activities or income and expenditure has been presented for the charity alone as permitted by section 408 of the Companies Act 2006.

1.14 Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

1.15 Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

1.16 Amended financial statements

These financial statements replace the financial statements originally approved by trustees on 16 April 2024. Expenditure has been reclassified to correctly represent the activity in the year. The amendment relates to expenditure on raising funds, trading activities and expenditure on charitable activities as set out in notes 3 to 5 of the financial statements.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

2 INCOME

	Unrestricted	Restricted £	2023 Total £
Income from donations and legacies			
Donations and gifts	647,668	120,728	768,396
Legacies	964,223	5,000	969,223
	1,611,891	125,728	1,737,619
Income from charitable activities			
Membership	1,129,754	-	1,129,754
Raising Awareness	812,281	35,475	847,756
Research	-	-	-
Groups	4,162	-	4,162
	1,946,197	35,475	1,981,672
Income from trading activities			
Raffle and lottery	443,732	-	443,732
Other commercial activities	23,007	-	23,007
	466,739	-	466,739
Investment Income			
Investments - dividends	24,454	-	24,454
Bank interest	40,545	-	40,545
	64,999	-	64,999
	4,089,826	161,203	4,251,029

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

2 INCOME (continued)

	Unrestricted	Restricted £	2022 Total £
Income from donations and legacies			
Donations and gifts	631,181	186,659	817,840
Legacies	708,235	40,027	748,262
	<u>1,339,416</u>	<u>226,686</u>	<u>1,566,102</u>
Income from charitable activities			
Membership	1,180,435	-	1,180,435
Raising Awareness	792,249	27,778	820,027
Research	-	-	-
Groups	32,469	-	32,469
	<u>2,005,153</u>	<u>27,778</u>	<u>2,032,931</u>
Income from trading activities			
Raffle and lottery	426,038	-	426,038
Other commercial activities	11,357	1,078	12,435
	<u>437,395</u>	<u>1,078</u>	<u>438,473</u>
Investment Income			
Investments - dividends	2,099	-	2,099
Bank interest	11,819	3,015	14,834
	<u>13,918</u>	<u>3,015</u>	<u>16,933</u>

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

3 Expenditure

	Unrestricted £	Restricted £	2023 Total £
Charitable activities			
Membership	1,307,322	-	1,307,322
Raising Awareness	1,476,870	122,143	1,599,013
Research	248,927	34,231	283,158
Groups	138,036	-	138,036
International	-	-	-
	<u>3,171,155</u>	<u>156,374</u>	<u>3,327,529</u>

Breakdown of costs of charitable activities

	Direct costs	Grants made (notes 6)	Support costs (note 4, 5)	2023 Total
Membership	1,004,387	-	302,935	1,307,322
Raising Awareness	1,261,025	-	337,988	1,599,013
Research	172,228	30,000	80,930	283,158
Groups	95,548	-	42,488	138,036
International	-	-	-	-
	<u>2,533,188</u>	<u>30,000</u>	<u>764,341</u>	<u>3,327,529</u>

Research cost breakdown

	Direct costs	Grants made	2023
Direct Research costs	172,228	30,000	202,228
Support costs (Note 5)	16,555	64,375	80,930
	<u>188,783</u>	<u>94,375</u>	<u>283,158</u>

All support costs are allocated on a headcount basis.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

3 Expenditure (continued)

	Unrestricted £	Restricted £	2022 Total £
Charitable activities			
Membership	1,147,572	-	1,147,572
Raising Awareness	1,380,566	110,679	1,491,245
Research	135,272	-	135,272
Groups	149,742	-	149,742
	<u>2,813,152</u>	<u>110,679</u>	<u>2,923,831</u>

Breakdown of costs of charitable activities

	Direct costs	Grants made (notes 6)	Support costs (note 4 ,5)	2022 Total
Membership	841,279	-	306,293	1,147,572
Raising Awareness	1,075,455	-	415,790	1,491,245
Research	90,754	-	44,518	135,272
Groups	98,281	-	51,461	149,742
	<u>2,105,769</u>	<u>-</u>	<u>818,062</u>	<u>2,923,831</u>

Research cost breakdown

	Direct costs	Grants made	2022
Direct Research costs	95,596	-	95,596
Support costs	6,131	38,387	44,518
	<u>101,727</u>	<u>38,387</u>	<u>140,114</u>

All support costs are allocated on a headcount basis.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

4 Total support cost breakdown by activity

	Staff costs £	Other costs £	2023 Total £
Cost of raising funds			
Donations and legacies	22,185	61,827	84,012
Trading activities	16,964	47,273	64,237
Charitable activities (note 3)	201,843	562,498	764,341
	240,992	671,598	912,590

	Staff costs £	Other costs £	2022 Total £
Cost of raising funds			
Donations and legacies	25,154	37,510	62,664
Trading activities	22,542	33,615	56,157
Charitable activities (note 3)	330,713	493,156	823,869
	378,409	564,281	942,690

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

5 Support cost apportionment

	Support staff	Depreciation	Governance	HR costs	IT costs £	Office costs £	2023 Total £
Expenditure on raising funds							
Donations and legacies	22,185	5,329	2,655	5,905	19,192	28,746	84,012
Trading activities	16,964	4,075	2,029	4,515	14,675	21,979	64,237
Charitable activities							
Membership	79,998	19,216	9,572	21,292	69,203	103,654	302,935
Raising awareness	89,254	21,440	10,680	23,755	77,211	115,648	337,988
Research	21,371	5,134	2,557	5,688	18,488	27,692	80,930
Groups	11,220	2,695	1,343	2,986	9,706	14,538	42,488
	240,992	57,889	28,836	64,141	208,475	312,257	912,590
	Support staff	Depreciation	Governance	HR costs	IT costs £	Office costs £	2022 Total £
Expenditure on raising funds							
Donations and legacies	25,154	2,832	1,844	4,847	8,951	19,036	62,664
Trading activities	22,542	2,538	1,652	4,344	8,021	17,059	56,156
Charitable activities							
Membership	123,823	13,942	9,076	23,861	44,060	93,706	308,468
Raising awareness	168,089	18,926	12,320	32,391	59,811	127,203	418,740
Research	17,997	2,026	1,319	3,468	6,404	13,620	44,834
Groups	20,804	2,342	1,525	4,009	7,403	15,744	51,828
	378,409	42,606	27,736	72,920	134,650	286,369	942,690

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

6 Grants payable

	Grants to institutions	
	2023 £	2022 £
Children and Young people's grant	30,000	-
	<u>30,000</u>	<u>-</u>

In accordance with the accounting policy outlined in note 1.5, only the first year of funding commitment is recognised on the accounts for multiyear grants which are conditional on an annual review of progress which determines if future funding is provided.

7 Net incoming (outgoing) resources for the year

This is stated after charging

	2023 £	2022 £
Depreciation and amortisation	66,866	46,495
Operating lease rentals	72,412	73,049
Trustees liability insurance	1,100	1,100
Audit services	15,835	13,575
Non - audit services provided by the auditor		
General advice	2,085	1,975
Tax compliance	895	845
	<u>159,193</u>	<u>137,039</u>

Travel costs amounting to £1,316 (2022 - £1,291) were reimbursed to 4 (2022 - 4) members of the Board of Trustees.

8 Staff costs and numbers

	2023 £	2022 £
Salaries and wages	1,860,552	1,527,899
Social security costs	192,822	162,417
Pension costs	98,961	81,842
	<u>2,152,335</u>	<u>1,772,158</u>

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

The number of employees whose salary amounted to over £60,000 during:

	2023 Number	2022 Number
£60,000 - £70,000	4	-
£70,000 - £80,000	-	-
£80,000 - £90,000	-	1
£90,000 - £100,000	-	-
£100,000 - £110,000	1	-

The key management personnel of the group (and charity) comprise the Trustees, the chief executive and senior management team. The total employee benefits (Salary, Employers National insurance and Employers pension) of the key management personnel of the group were £652,893 (2022: £350,825). None of the Trustees have been paid any remuneration or received any benefits for performing their role as Trustee of the charity.

No termination payments for payments in lieu of notice (PILON) were paid in the year (2022: £10,414).

The average monthly number of employees during the year, calculated on the basis of average headcount was as follows:

	2023 Number	2022 Number
Advice and information	43	39
Administration and support	9	7
	52	46

9 Taxation

The charitable company is exempt from Corporation Tax on its charitable activities under Sections 466 to 493 of the Corporation Tax Act 2010.

10 Fixed assets - Group

	Intangible Assets £	Furniture & fittings £	Computer equipment £	Total £
Cost				
At 1 January 2023	297,172	152,592	552,440	705,032
Additions	54,010	141,000	10,806	151,806
Disposals	(172,082)	(152,592)	(531,841)	(684,433)
At 31 December 2023	179,100	141,000	31,405	172,405
Amortisation and depreciation				
At 1 January 2023	191,908	151,981	524,483	676,464
Charge for the year	55,811	-	11,055	11,055
Eliminated on disposal	(183,791)	(151,981)	(520,129)	(672,110)
At 31 December 2023	63,928	-	15,409	15,409
Net book values				
At 31 December 2023	115,172	141,000	15,996	156,996
At 31 December 2022	105,264	611	27,957	28,568

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

10 Fixed assets - Charity

	Intangible Assets £	Furniture & fittings £	Computer equipment £	Total £
Cost				
At 1 January 2023	297,172	152,592	552,440	705,032
Additions	167,808	141,000	10,806	151,806
Disposals	(172,082)	(152,592)	(531,841)	(684,433)
Impairment	(113,798)	-	-	-
At 31 December 2023	179,100	141,000	31,405	172,405
Amortisation and depreciation				
At 1 January 2023	191,908	151,981	524,483	676,464
Charge for the year	55,811	-	(8,556)	(8,556)
Eliminated on disposal	(183,791)	(151,981)	(500,517)	(652,498)
At 31 December 2023	63,928	-	15,410	15,410
Net book values				
At 31 December 2023	115,172	141,000	15,995	156,995
At 31 December 2022	105,264	611	27,957	28,568

11 Fixed asset investments - Group And Charity

	(Charity only) Investments in subsidiaries £	Unit trusts £	Total 2023 £	Total 2022 £
Market Value at 1 January	2	323,848	323,850	2
Additions	-	634,783	634,783	340,000
Disposals	-	-	-	-
Realised investment gains/(losses)	-	23,947	23,947	(16,152)
Market Value at 31 December	2	982,578	982,580	323,850
Historical cost as at 31 December 2023	2	974,783	974,785	340,002

Holdings of more than 20%

The charitable company holds more than 20% of the share capital in the following company:

Company	Country of incorporation	Class	Shares held	%
The Coeliac Trading Company Ltd	England & Wales	Ordinary		100

The principal activity of The Coeliac Trading Company Limited (Company number 02856981) is to raise funds on a commercial basis for Coeliac UK (Limited by Guarantee), a registered charity. The address of the registered office is Artisan, Hillbottom Road, Sands Industrial Estate, High Wycombe, Buckinghamshire, HP12 4HJ.

The aggregate amount of capital and reserves and the results of this undertaking for the year ended 31 December 2023 were:

	Capital £	Profits to reserves for the year £
The Coeliac Trading Company Ltd	2	-

During 2023 the Trading Company proposed to donate its entire profits and reserves of £123,360 (2022: £2,655) to Coeliac UK. The profits are net of income and expenditure totalling £250,132 (2022: £290,203) and £240,750 (2022: £287,548) respectively. Additionally, the company made a surplus on disposal of its operations to Coeliac UK totalling £113,798.

Current asset investments and deposits held relate exclusively to cash deposit accounts and amounted to £nil (2022: £623,357) as shown on the balance sheet.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

12 Debtors

	Group		Charity	
	2023 £	2022 £	2023 £	2022 £
Trade debtors	142,846	122,290	142,846	87,411
Income tax and VAT recoverable	75,124	-	75,124	-
Amounts owed by group undertakings	-	-	111,904	238,348
Prepayments and accrued income	1,386,720	885,809	1,386,720	885,809
	1,604,690	1,008,099	1,716,594	1,211,568

13 Creditors: amounts falling due within one year

	Group		Charity	
	2023 £	2022 £	2023 £	2022 £
Grants payable	136,080	194,230	136,080	194,230
Trade creditors	372,192	286,136	372,192	276,495
Other tax and social security	52,940	11,448	52,940	2,571
Accruals	307,856	122,112	307,856	117,062
Deferred income	503,204	523,904	503,204	490,481
	1,372,272	1,137,830	1,372,272	1,080,839

Deferred income - Charity

	2023 £	2022 £
At 1 January 2023	490,481	456,905
Released in 2023	(467,545)	(401,470)
Membership, licencing, Lottery and sponsorship income received in advance	480,265	435,046
At 31 December 2023	503,201	490,481

14 Provision for liabilities and charges - Group and Charity

	£
At 1 January 2023	40,000
Charged for the year	(40,000)
At 31 December 2023	-

The brought forward provision related to dilapidations costs payable at the end of the parent charity and group's tenancy at its previous address which concluded in the year.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

15 Designated funds - Group and Charity

	Balance at 01-Jan-23	Incoming	Outgoing	Balance at 31-Dec-23
Research (Innovate)	2,314	-	(2,314)	-
Research Fund	10,194	2,314	(103)	12,405
Local voluntary support groups	85,783	6,568	(11,533)	80,818
	98,291	8,882	(13,950)	93,223

	Balance at 01-Jan-22	Incoming	Outgoing	Balance at 31-Dec-22
Research (Innovate)	2,314	-	-	2,314
Research Fund	10,194	-	-	10,194
Local voluntary support groups	81,058	32,469	(27,744)	85,783
	93,566	32,466	(27,741)	98,291

Research, including Innovate

Income to be used for funding medical research into Coeliac disease and dermatitis herpetiformis, designated by the Board from unrestricted funds.

Local voluntary support groups

The collective funds held and administered by Volunteer Groups, representing their working funds.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

16 Restricted funds - Group and Charity

	Balance at 01-Jan-23	Incoming	Outgoing	Investment losses	Transfer of funds	Balance at 31-Dec-23
Research Fund	499,056	91,674	(97,980)	(526)	-	492,224
Daily newspaper advert for Awareness Week	1,529	-	-	(41)	-	1,488
Awareness Week	-	35,028	(59,809)	-	24,782	1
Care System campaigns	17	-	-	(17)	-	-
Membership Helpline	165	1	-	-	-	166
Diagnosis TV Advert	2,947	-	(2,947)	-	-	-
Diagnosis Life Channel NHS	2,014	-	(2,014)	-	-	-
Pharmacy Packs	1,075	-	-	(2)	-	1,073
Diagnosis campaign	37,732	-	8,390	(240)	(24,782)	21,100
Events for children with CD and families	5,036	-	-	(9)	-	5,027
Digital Campaign	2,014	-	(2,014)	-	-	-
Gluten Ataxia	7,770	34,500	-	(14)	-	42,256
Sponsored Dissertations	7,500	-	-	-	-	7,500
	566,855	161,203	(156,374)	(851)	-	570,833

	Balance at 01-Jan-22	Incoming	Outgoing	Investment gains/(losses)	Transfer of funds	Balance at 31-Dec-22
Research Fund	277,208	230,576	-	(1,229)	(7,500)	499,056
Daily newspaper advert for Awareness Week	1,477	41	-	11	-	1,529
Care System campaigns	17	-	-	-	-	17
Membership Helpline	140	24	-	1	-	165
Diagnosis TV Advert	2,926	-	-	21	-	2,947
Diagnosis Life Channel NHS	2,000	-	-	14	-	2,014
Pharmacy Packs	1,067	-	-	8	-	1,075
Diagnosis campaign	119,767	27,778	(110,679)	866	-	37,732
Events for children with CD and families	5,000	-	-	36	-	5,036
Digital Campaign	2,000	-	-	14	-	2,014
Gluten Ataxia	7,578	137	-	55	-	7,770
Sponsored Dissertations	-	-	-	-	7,500	7,500
	419,180	258,557	(110,679)	(203)	-	566,855

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

16 Restricted funds - Group and Charity

The principal purposes for the above restricted funds were as follows:

Research

Income received to be used solely for funding medical research into coeliac disease and dermatitis herperiformis (DH).

Local support

The collective funds held and administered by Volunteer Groups.

Daily newspaper advert for Awareness Week

Donations towards an advertisement to be placed in a major national newspaper during Awareness Week to raise the profile of Coeliac disease.

Care System campaign

Campaign to improve awareness in the care system.

Membership Helpline

Funding for ongoing costs of providing the Coeliac UK Helpline.

Diagnosis TV Advert

TV advertising campaign to improve diagnosis rates for Coeliac disease.

Diagnosis Life Channel NHS

Advertising campaign for patients via Life Channel in GP surgeries to raise awareness of Coeliac disease.

Pharmacy packs

Donations towards production of pharmacy information packs.

Digital Campaign

Donations toward developing our digital communication materials

Gluten Ataxia

Income to fund a project to achieve an earlier diagnosis for those with Gluten Ataxia.

Events for children with CD and families

Funds to be used by Coeliac UK for events to benefit coeliac children and their families.

Diagnosis Campaign

Funds have been granted to pay for the development of campaign materials to promote diagnosis of Coeliac disease in children in support of ongoing activities regarding awareness and education on Coeliac disease.

Awareness Week

Funds have been granted to support the Awareness week campaign of Coeliac disease in support of ongoing activities regarding awareness and education on Coeliac disease.

Sponsored Dissertations

Funds to be used by Coeliac UK to sponsor students' dissertations aimed at the advancement of awareness and research related to Coeliac disease.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

17 Analysis of net assets between funds - Charity and group

	Unrestricted funds 2023	Designated funds 2023	Restricted funds 2023	Total 2023
Intangible assets	115,172	-	-	115,172
Tangible assets	156,996	-	-	156,996
Investments*	982,580	-	-	982,580
Net current assets less provisions for liabilities and charges	837,903	93,223	570,833	1,501,960
	<u>2,092,651</u>	<u>93,223</u>	<u>570,833</u>	<u>2,756,708</u>

* Group investments excludes the Charity's £2 investment in the share capital of the subsidiary company.

	Unrestricted funds 2022	Designated funds 2022	Restricted funds 2022	Total 2022
Intangible assets	105,264	-	-	105,264
Tangible assets	28,568	-	-	28,568
Investments	323,848	-	-	323,848
Net current assets less provisions for liabilities and charges	1,480,747	98,291	566,855	2,145,893
	<u>1,938,427</u>	<u>98,291</u>	<u>566,855</u>	<u>2,603,573</u>

* Group investments excludes the Charity's £2 investment in the share capital of the subsidiary company.

18 Lease commitments - Charity and group

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	Land and buildings		Office equipment	
	2023 £	2022 £	2023 £	2022 £
Within one year	76,688	86,295	2,979	2,991
Between two and five years	306,753	5,103	9,772	3,132
More than five years	63,798	-	-	-
	<u>447,239</u>	<u>91,398</u>	<u>12,751</u>	<u>6,123</u>

19 Voluntary help

The charity had extra support from 250 volunteers in 2023 (2022: 370). The benefit of their contribution is not reflected in the financial statements.

20 Related party transactions

Coeliac UK holds 100% of the share capital of The Coeliac Trading Company Limited. Details of transactions in the year and balances at the year end are detailed in note 11.

There were no other related party transactions in the reporting period that require disclosure.

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

21 Pension commitments

The estimated pension deficit as at 31 December 2023 is £815 (31 December 2022: £1,533). This is in accordance with the most recent independent valuation performed on 30 September 2020. Under the new recovery plan, from 1 April 2023 the deficit contributions that are required from Coeliac UK are £772 a year, payable in monthly instalments of £64.32. These payments do not increase.

The deficit contributions agreed between the company and scheme at the yearend date are as follows:

Year	Amount
1	772
2	64

The present value of the future provision for Coeliac UK is calculated as follows:

	2023	2022
Provision at the start of the period	1,533	2,653
Discount factor interest expense	55	23
Deficit contribution paid	(772)	(1,086)
Remeasurement - impact of change in assumptions	(1)	(57)
Provision at end of period 31 December	815	1,533

The current deficit of £815 is being paid at an immaterial amount to the charity on an annual basis, this deficit would only fall due in its entirety should the charity decides to withdraw from the scheme, the Board of Trustees currently have no plans short or long term to withdraw from this scheme.

22 Reconciliation of net income/(expenditure) for the reporting period (as per the SOFA)

	2023	2022
	£	£
Net income/(expenditure) for the reporting period (as per the SOFA)	153,135	522,675
Adjustments for:		
Amortisation and depreciation charges	66,866	46,496
(Gains)/losses on investments	(23,947)	16,152
Dividends from investments	(24,454)	(2,099)
Bank interest	(40,545)	(14,833)
Increase in debtors	(596,591)	(552,318)
Increase/(decrease) in creditors	194,442	(16,192)
Other gains/losses	614	-
Net cash provided by operating activities	<u>(270,481)</u>	<u>(119)</u>

Coeliac UK

Annual Report and Financial Statements for the year ended 31 December 2023

Notes to the financial statements

23 Analysis of cash and cash equivalents

	2023 £	2022 £
Cash in hand	240	1,202
Notice deposits (less than 3 months)	1,269,262	2,314,421
Total cash and cash equivalents	<u>1,269,502</u>	<u>2,315,623</u>

Analysis of changes in net debt

	Balance at 01-Jan-23	Cash flows	Balance at 31-Dec-23
Cash	1,202	(962)	240
Cash equivalents	2,314,421	(1,045,159)	1,269,262
	<u>2,315,623</u>	<u>(1,046,121)</u>	<u>1,269,502</u>